A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

To join this study, you need to be an adult between 18 and 75 years old. Doctors will need to have diagnosed you with a specific type of kidney disease called Primary Membranous Nephropathy, and tests must show you have particular antibodies (anti-PLA2R) in your blood. You should also be taking standard medicines for your kidney condition, like ACE inhibitors or ARBs, unless you can't take them for medical reasons. It's important that your vaccinations, such as for flu and COVID-19, are up to date.

There are also some reasons why you might not be able to join. For example, if you've recently had certain immune-system treatments in the last few months, or if you have other serious health problems like uncontrolled diabetes, certain types of cancer, or specific heart, lung, or brain conditions. If you're currently taking high doses of steroid medication, this might also mean you can't take part. The study team will carefully check all your health information to see if this study is right for you.

If you decide to join this study, it will be divided into different parts and will last for up to 26 months. First, there's a screening period where doctors will do tests to make sure the study is suitable for you. After that, if you qualify, you'll enter the treatment period where you'll receive the study medicine, Surovatamig, given as an injection under your skin. You'll have regular visits to the clinic so the study team can monitor your health, check for any side effects, and see how the medicine is affecting your kidney disease. There will also be a follow-up period after you finish taking the medicine to continue monitoring your health and gather more information.